William Blair Initiates Coverage On Arcturus Therapeutics with Outperform Rating, Announces Price Target of $71
Portfolio Pulse from richadhand@benzinga.com
William Blair analyst Myles Minter has initiated coverage on Arcturus Therapeutics (NASDAQ:ARCT) with an Outperform rating and a price target of $71.
July 24, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics has been given an Outperform rating and a price target of $71 by William Blair analyst Myles Minter.
The Outperform rating and price target of $71 by William Blair analyst Myles Minter is a positive signal for Arcturus Therapeutics. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100